Lisa Miron JD and Robert Oldham Young*

Department of Research, Innerlight, Biological Research and Health Education Foundation, USA

*Corresponding Author: Robert Oldham Young, Department of Research, Innerlight, Biological Research and Health Education Foundation, USA.

Received: December 13, 2024; Published: April 21, 2025

Abstract

Lupron (leuprolide acetate) is a gonadotropin-releasing hormone (GnRH) agonist widely utilized in medical treatments for conditions such as prostate cancer, endometriosis, transgender hormone therapy, and precocious puberty. While effective, Lupron is associated with significant adverse effects, including osteoporosis, cardiovascular complications, psychological disturbances, metabolic disruptions, and cancer risks. This review provides an evidence-based analysis of Lupron’s clinical applications, mechanisms of action, and side effects, while critically addressing natural solutions to glandular imbalances and the primary causes of dysfunction.

 Keywords: Lupron; Gonadotropin-Releasing Hormone Agonist; Hormone Therapy; Prostate Cancer; Endometriosis; Transgender Hormone Therapy; Glandular Dysfunction; Alkaline Interstitial Environment; Osteoporosis; Cardiovascular Risk; Cancer Risk; Metabolic Waste Products; Acidic Diet; Electromagnetic Radiation; Chemical Exposure

References

1. Shahinian V B., et al. “Risk of fracture after androgen deprivation for prostate cancer”. New England Journal of Medicine 2 (2005): 154-164.
2. Carr BR and Marshburn PB. “GnRH agonists: Clinical applications in gynecology”. Fertility and Sterility 4 (1994): 691-702.
3. Hembree W C., et al. “Endocrine treatment of gender-dysphoric/gender-incongruent persons”. Endocrine Society Guidelines (2017).
4. Kaplowitz PB. “Treatment of precocious puberty”. Current Opinion in Endocrinology, Diabetes, and Obesity 1 (2009): 25-32.
5. Smith MR., et al. “Osteoporosis and fractures in androgen-deprived prostate cancer patients”. Cancer 12 (2001): 2238-2245.
6. Lawyer Lisa. “Lupron-induced osteoporosis”. Substack Article (2020).
7. Medical News Today. “Hormone therapies for cancer”. (2020).
8. Hansen PJ., et al. “Gonadotropin-releasing hormone agonist therapy for precocious puberty”. Journal of Clinical Endocrinology and Metabolism9 (1996): 3437-3443.
9. “Hormone therapies and long-term risk”. (2019).
10. “Adverse outcomes in androgen-deprived patients”. Oncotarget Journal (2017).
11. QuickRx Specialty Pharmacy. “Lupron in transgender therapy”. (2021).
12. Smith MR. “The long-term effects of GnRH agonists on cardiovascular risk in prostate cancer patients”. Cancer Treatment Reviews3 (2006): 237-244.
13. Bhasin S and Cunningham GR. “Testosterone effects on bone health and metabolism: Evidence from androgen deprivation therapy”. Journal of Clinical Endocrinology and Metabolism11 (2010): 4825-4832.
14. Goodman J and Costello J. “Psychological effects of long-term hormonal suppression in cancer treatment”. American Journal of Psycho-Oncology2 (2012): 123-129.
15. Thomas R J and Williams LD. “Alkaline diet interventions for cancer prevention and detoxification. Nutrition and Cancer 70.3 (2018): 450-458.
16. Brodin T. “Chemical pollutants as endocrine disruptors: Impacts on glandular function”. Toxicological Studies 3 (2013): 243-251.
17. Greaves M. “Detoxifying the glandular system: A review”. Journal of Metabolic Health2 (2017): 67-75.
18. Jones G and Chapman LM. “Nutritional interventions for improving bone health in hormone-treated cancer patients”. Bone Journal6 (2012): 12-19.
19. Zhao, W and Zeng, L. (2018). Adaptogenic herbs for adrenal and thyroid health”. Journal of Herbal Medicine4 (2018): 231-237.
20. Hormone Endocrinology Institute. “Hormones as metabolic waste products: A biochemical perspective”. Journal of Biochemical Research2 (2018): 341-348.
21. Carpenter WJ and Dillon MT. “Functional roles of endocrine glands in immune modulation”. Immunology and Endocrinology1 (2015): 97-104.
22. Roberts D E and Jenkins M. “Metabolic changes in prostate cancer patients undergoing GnRH agonist treatment”. Metabolism Journal9 (2009): 14-19.
23. Klotz L. “Hormonal therapy for prostate cancer: Mechanisms of action and risks”. Journal of Urology3 (2003): 16-20.
24. Anderson J H., et al. “Electromagnetic fields and their effects on human physiology”. International Journal of Environmental Research and Public Health14 (2020): 5053.
25. “Pituitary impacts of GnRH agonist therapies”. Journal of Endocrinology 156.4 (2019): 25-33.
26. Anand S. “Secondary malignancies associated with hormone therapy”. Clinical Cancer Research2 (2015): 13-18.
27. Lawyer Lisa. “Chemical menopause and Lupron side effects”. Substack Article.
28. Goodman J and Costello J. “Psychological effects of long-term hormonal suppression in cancer treatment”. Psycho-Oncology2 (2012): 123-129.
29. Thomas R J and Williams LD. “Alkaline diet interventions for cancer prevention and detoxification. Nutrition and Cancer3 (2018): 450-458.
30. Zhao W and Zeng L. “Adaptogenic herbs for adrenal and thyroid health”. Journal of Herbal Medicine4 (2018): 231-237.
31. Jones G and Chapman LM. “Nutritional interventions for improving bone health in hormone-treated cancer patients”. Bone Journal6 (2012): 12-19.
32. Greaves M. “Detoxifying the glandular system: A review”. Journal of Metabolic Health2 (2017): 67-75.
33. Brodin T. “Chemical pollutants as endocrine disruptors: Impacts on glandular function”. Toxicological Studies 3 (2013): 243-251.
34. Hormone Endocrinology Institute. “Hormones as metabolic waste products: A biochemical perspective”. Journal of Biochemical Research2 (2018): 341-348.
35. Carpenter WJ and Dillon MT. “Functional roles of endocrine glands in immune modulation”. Immunology and Endocrinology1 (2015): 97-104.
36. Young RO and Young SR. “The pH Miracle: Balance Your Diet, Reclaim Your Health”. Revised and Updated Edition. Grand Central Life & Style (2010).
37. Young RO. “Detoxification through the use of natural zeolites and sea minerals. A supplement to the pH Miracle protocols” (2010).
38. Brodin, T. “Chemical pollutants as endocrine disruptors: Impacts on glandular function”. Toxicological Studies3 (2013): 243-251.
39. Anderson, C. “Mind-body techniques for endocrine balance”. International Journal of Stress Management 23.2 (2016): 34-42.
40. Thomas RJ and Williams LD. “Alkaline diet interventions for cancer prevention and detoxification”. Nutrition and Cancer3 (2018): 450-458.
41. Carpenter W J and Dillon M T. “Unctional roles of endocrine glands in immune modulation”. Immunology and Endocrinology1 (2015): 97-104.
42. Roberts D E and Jenkins M. “Metabolic changes in prostate cancer patients undergoing GnRH agonist treatment”. Metabolism Journal9 (2009): 14-19.
43. Klotz L. “Hormonal therapy for prostate cancer: Mechanisms of action and risks”. Journal of Urology3 (2003): 16-20.
44. MasterPeace Zeolite Z. “Natural detoxification with zeolites”.
45. SOLergy Sea Minerals. “The role of sea minerals in restoring health”.

Citation

Citation: Lisa Miron JD and Robert Oldham Young. “The Use and Side Effects of Lupron in Men, Women, and Children: Comprehensive Review Article”.Acta Scientific Medical Sciences 9.5 (2025): 145-149.

Copyright

Copyright: © 2025 Lisa Miron JD and Robert Oldham Young. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.